nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—Respiratory tract congestion—Varenicline—nicotine dependence	0.0578	0.101	CcSEcCtD
Dexmedetomidine—Pharyngolaryngeal pain—Varenicline—nicotine dependence	0.0312	0.0544	CcSEcCtD
Dexmedetomidine—Laryngeal pain—Varenicline—nicotine dependence	0.0309	0.0539	CcSEcCtD
Dexmedetomidine—CYP2E1—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0262	0.0615	CbGpPWpGaD
Dexmedetomidine—Leukocytosis—Varenicline—nicotine dependence	0.0224	0.0391	CcSEcCtD
Dexmedetomidine—Hyperkalaemia—Varenicline—nicotine dependence	0.0207	0.0361	CcSEcCtD
Dexmedetomidine—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0186	0.0436	CbGpPWpGaD
Dexmedetomidine—Renal failure acute—Varenicline—nicotine dependence	0.0166	0.0289	CcSEcCtD
Dexmedetomidine—CYP2E1—Xenobiotics—CYP2A7—nicotine dependence	0.0162	0.0381	CbGpPWpGaD
Dexmedetomidine—Atrial fibrillation—Varenicline—nicotine dependence	0.0162	0.0281	CcSEcCtD
Dexmedetomidine—Thirst—Varenicline—nicotine dependence	0.0161	0.028	CcSEcCtD
Dexmedetomidine—Hypoglycaemia—Varenicline—nicotine dependence	0.0157	0.0273	CcSEcCtD
Dexmedetomidine—CYP1A1—Xenobiotics—CYP2A7—nicotine dependence	0.0153	0.0359	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.0145	0.034	CbGpPWpGaD
Dexmedetomidine—Hypokalaemia—Varenicline—nicotine dependence	0.0139	0.0243	CcSEcCtD
Dexmedetomidine—Abdominal distension—Varenicline—nicotine dependence	0.0133	0.0232	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Varenicline—nicotine dependence	0.0119	0.0208	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Varenicline—nicotine dependence	0.0116	0.0203	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Varenicline—nicotine dependence	0.0116	0.0201	CcSEcCtD
Dexmedetomidine—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.0115	0.027	CbGpPWpGaD
Dexmedetomidine—ADRA1D—G alpha (12/13) signalling events—FGD1—nicotine dependence	0.0109	0.0256	CbGpPWpGaD
Dexmedetomidine—Bradycardia—Varenicline—nicotine dependence	0.0108	0.0188	CcSEcCtD
Dexmedetomidine—Hallucination—Varenicline—nicotine dependence	0.0105	0.0184	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Varenicline—nicotine dependence	0.0104	0.0182	CcSEcCtD
Dexmedetomidine—Visual impairment—Varenicline—nicotine dependence	0.0102	0.0178	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Varenicline—nicotine dependence	0.00983	0.0171	CcSEcCtD
Dexmedetomidine—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00975	0.0229	CbGpPWpGaD
Dexmedetomidine—Angiopathy—Varenicline—nicotine dependence	0.00961	0.0167	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Varenicline—nicotine dependence	0.00955	0.0166	CcSEcCtD
Dexmedetomidine—Chills—Varenicline—nicotine dependence	0.00951	0.0166	CcSEcCtD
Dexmedetomidine—Arrhythmia—Varenicline—nicotine dependence	0.00946	0.0165	CcSEcCtD
Dexmedetomidine—Mental disorder—Varenicline—nicotine dependence	0.00928	0.0162	CcSEcCtD
Dexmedetomidine—Malnutrition—Varenicline—nicotine dependence	0.00922	0.0161	CcSEcCtD
Dexmedetomidine—ADRA1B—G alpha (12/13) signalling events—FGD1—nicotine dependence	0.00906	0.0213	CbGpPWpGaD
Dexmedetomidine—Anaemia—Varenicline—nicotine dependence	0.00852	0.0148	CcSEcCtD
Dexmedetomidine—Agitation—Varenicline—nicotine dependence	0.00847	0.0148	CcSEcCtD
Dexmedetomidine—ADRA1D—Monoamine GPCRs—DRD2—nicotine dependence	0.00817	0.0192	CbGpPWpGaD
Dexmedetomidine—Convulsion—Varenicline—nicotine dependence	0.00799	0.0139	CcSEcCtD
Dexmedetomidine—Hypertension—Varenicline—nicotine dependence	0.00796	0.0139	CcSEcCtD
Dexmedetomidine—Anxiety—Varenicline—nicotine dependence	0.00782	0.0136	CcSEcCtD
Dexmedetomidine—Dry mouth—Varenicline—nicotine dependence	0.00768	0.0134	CcSEcCtD
Dexmedetomidine—Infection—Varenicline—nicotine dependence	0.00748	0.013	CcSEcCtD
Dexmedetomidine—ADRA2B—Monoamine GPCRs—DRD2—nicotine dependence	0.00738	0.0173	CbGpPWpGaD
Dexmedetomidine—Thrombocytopenia—Varenicline—nicotine dependence	0.00737	0.0128	CcSEcCtD
Dexmedetomidine—Tachycardia—Varenicline—nicotine dependence	0.00735	0.0128	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Varenicline—nicotine dependence	0.00728	0.0127	CcSEcCtD
Dexmedetomidine—Hypotension—Varenicline—nicotine dependence	0.00703	0.0123	CcSEcCtD
Dexmedetomidine—ADRA2C—Monoamine GPCRs—DRD2—nicotine dependence	0.00689	0.0162	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00687	0.0161	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Monoamine GPCRs—DRD2—nicotine dependence	0.00678	0.0159	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00674	0.0158	CbGpPWpGaD
Dexmedetomidine—Dyspnoea—Varenicline—nicotine dependence	0.00671	0.0117	CcSEcCtD
Dexmedetomidine—Somnolence—Varenicline—nicotine dependence	0.00669	0.0117	CcSEcCtD
Dexmedetomidine—CYP2E1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00665	0.0156	CbGpPWpGaD
Dexmedetomidine—Gastrointestinal disorder—Varenicline—nicotine dependence	0.0065	0.0113	CcSEcCtD
Dexmedetomidine—Constipation—Varenicline—nicotine dependence	0.00644	0.0112	CcSEcCtD
Dexmedetomidine—Pain—Varenicline—nicotine dependence	0.00644	0.0112	CcSEcCtD
Dexmedetomidine—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00635	0.0149	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00627	0.0147	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Amine ligand-binding receptors—DRD2—nicotine dependence	0.0062	0.0146	CbGpPWpGaD
Dexmedetomidine—Feeling abnormal—Varenicline—nicotine dependence	0.0062	0.0108	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Varenicline—nicotine dependence	0.00615	0.0107	CcSEcCtD
Dexmedetomidine—Abdominal pain—Varenicline—nicotine dependence	0.00595	0.0104	CcSEcCtD
Dexmedetomidine—Body temperature increased—Varenicline—nicotine dependence	0.00595	0.0104	CcSEcCtD
Dexmedetomidine—ADRA2C—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00579	0.0136	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Amine ligand-binding receptors—DRD2—nicotine dependence	0.0057	0.0134	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Monoamine GPCRs—DRD2—nicotine dependence	0.0056	0.0131	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00546	0.0128	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00515	0.0121	CbGpPWpGaD
Dexmedetomidine—Diarrhoea—Varenicline—nicotine dependence	0.00515	0.00897	CcSEcCtD
Dexmedetomidine—ADRA2B—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00503	0.0118	CbGpPWpGaD
Dexmedetomidine—Dizziness—Varenicline—nicotine dependence	0.00498	0.00867	CcSEcCtD
Dexmedetomidine—Vomiting—Varenicline—nicotine dependence	0.00479	0.00834	CcSEcCtD
Dexmedetomidine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00478	0.0112	CbGpPWpGaD
Dexmedetomidine—Rash—Varenicline—nicotine dependence	0.00475	0.00827	CcSEcCtD
Dexmedetomidine—Dermatitis—Varenicline—nicotine dependence	0.00474	0.00826	CcSEcCtD
Dexmedetomidine—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00472	0.0111	CbGpPWpGaD
Dexmedetomidine—Headache—Varenicline—nicotine dependence	0.00471	0.00821	CcSEcCtD
Dexmedetomidine—ADRA2A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00471	0.011	CbGpPWpGaD
Dexmedetomidine—ADRA2C—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.0047	0.011	CbGpPWpGaD
Dexmedetomidine—Nausea—Varenicline—nicotine dependence	0.00447	0.00779	CcSEcCtD
Dexmedetomidine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00405	0.00951	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.004	0.00938	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00388	0.0091	CbGpPWpGaD
Dexmedetomidine—ADRA2A—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00382	0.00897	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—TAS2R16—nicotine dependence	0.00338	0.00793	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00328	0.00771	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00308	0.00723	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—TAS2R16—nicotine dependence	0.00305	0.00716	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.0029	0.00681	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Biological oxidations—CYP2A7—nicotine dependence	0.0029	0.00681	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00286	0.00672	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—TAS2R16—nicotine dependence	0.00285	0.00669	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—TAS2R16—nicotine dependence	0.0028	0.00658	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Biological oxidations—CYP2A7—nicotine dependence	0.00274	0.00642	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0027	0.00633	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—TAS2R16—nicotine dependence	0.00231	0.00543	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00218	0.00513	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00218	0.00512	CbGpPWpGaD
Dexmedetomidine—ADRA2B—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00212	0.00498	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.00206	0.00483	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00203	0.00477	CbGpPWpGaD
Dexmedetomidine—ADRA2C—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00198	0.00465	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00197	0.00462	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00191	0.00448	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00187	0.00439	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00185	0.00434	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00184	0.00432	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00181	0.00425	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00181	0.00425	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.00174	0.00409	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—TAS2R16—nicotine dependence	0.00173	0.00407	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00172	0.00404	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00172	0.00404	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00169	0.00396	CbGpPWpGaD
Dexmedetomidine—ADRA2A—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00161	0.00378	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00161	0.00378	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00158	0.00372	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00158	0.0037	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00158	0.0037	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—TAS2R16—nicotine dependence	0.00156	0.00367	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00155	0.00364	CbGpPWpGaD
Dexmedetomidine—ADRA2B—G alpha (i) signalling events—DRD2—nicotine dependence	0.00153	0.0036	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—FGD1—nicotine dependence	0.0015	0.00352	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00149	0.00351	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—TAS2R16—nicotine dependence	0.00146	0.00343	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—TAS2R16—nicotine dependence	0.00144	0.00338	CbGpPWpGaD
Dexmedetomidine—ADRA2C—G alpha (i) signalling events—DRD2—nicotine dependence	0.00143	0.00337	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00142	0.00334	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—OPRM1—nicotine dependence	0.00142	0.00334	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—FGD1—nicotine dependence	0.00136	0.00319	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—FGD1—nicotine dependence	0.00135	0.00317	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00135	0.00317	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00133	0.00312	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00131	0.00307	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00131	0.00307	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—OPRM1—nicotine dependence	0.00129	0.00302	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00128	0.00301	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—FGD1—nicotine dependence	0.00126	0.00296	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—FGD1—nicotine dependence	0.00124	0.00292	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—FGD1—nicotine dependence	0.00123	0.00288	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00122	0.00286	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—OPRM1—nicotine dependence	0.0012	0.00282	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—TAS2R16—nicotine dependence	0.00119	0.00279	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—OPRM1—nicotine dependence	0.00118	0.00277	CbGpPWpGaD
Dexmedetomidine—ADRA2A—G alpha (i) signalling events—DRD2—nicotine dependence	0.00116	0.00273	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—FGD1—nicotine dependence	0.00115	0.00269	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00114	0.00268	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—FGD1—nicotine dependence	0.00113	0.00265	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00112	0.00263	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00108	0.00254	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—DRD2—nicotine dependence	0.00103	0.00242	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—FGD1—nicotine dependence	0.00103	0.00241	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TAS2R16—nicotine dependence	0.00102	0.0024	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—OPRM1—nicotine dependence	0.000975	0.00229	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—FGD1—nicotine dependence	0.000931	0.00219	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—DRD2—nicotine dependence	0.000929	0.00218	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000926	0.00217	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TAS2R16—nicotine dependence	0.000924	0.00217	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—DRD2—nicotine dependence	0.000868	0.00204	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TAS2R16—nicotine dependence	0.000863	0.00203	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—DRD2—nicotine dependence	0.000854	0.00201	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TAS2R16—nicotine dependence	0.00085	0.00199	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—OPRM1—nicotine dependence	0.000804	0.00189	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—FGD1—nicotine dependence	0.000803	0.00189	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—OPRM1—nicotine dependence	0.00073	0.00171	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—OPRM1—nicotine dependence	0.000726	0.0017	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—FGD1—nicotine dependence	0.000725	0.0017	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—AKR1B10—nicotine dependence	0.000709	0.00167	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—DRD2—nicotine dependence	0.000705	0.00165	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TAS2R16—nicotine dependence	0.000701	0.00165	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—OPRM1—nicotine dependence	0.000678	0.00159	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—FGD1—nicotine dependence	0.000677	0.00159	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—OPRM1—nicotine dependence	0.000668	0.00157	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—FGD1—nicotine dependence	0.000667	0.00157	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CYP2A7—nicotine dependence	0.000665	0.00156	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—OPRM1—nicotine dependence	0.000659	0.00155	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—AKR1B10—nicotine dependence	0.000641	0.0015	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—OPRM1—nicotine dependence	0.000616	0.00145	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—OPRM1—nicotine dependence	0.000606	0.00142	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AKR1B10—nicotine dependence	0.000598	0.0014	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AKR1B10—nicotine dependence	0.000589	0.00138	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—DRD2—nicotine dependence	0.000582	0.00137	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—OPRM1—nicotine dependence	0.000551	0.00129	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FGD1—nicotine dependence	0.00055	0.00129	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CYP2A7—nicotine dependence	0.00054	0.00127	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—DRD2—nicotine dependence	0.000528	0.00124	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—DRD2—nicotine dependence	0.000525	0.00123	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—OPRM1—nicotine dependence	0.0005	0.00117	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—WASF2—nicotine dependence	0.0005	0.00117	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CYP2A7—nicotine dependence	0.000496	0.00116	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—DRD2—nicotine dependence	0.00049	0.00115	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKR1B10—nicotine dependence	0.000486	0.00114	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—DRD2—nicotine dependence	0.000483	0.00113	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—WASF1—nicotine dependence	0.000479	0.00113	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—DRD2—nicotine dependence	0.000477	0.00112	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CYP2A7—nicotine dependence	0.000468	0.0011	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—WASF2—nicotine dependence	0.000451	0.00106	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—DRD2—nicotine dependence	0.000445	0.00105	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—DRD2—nicotine dependence	0.000438	0.00103	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—WASF1—nicotine dependence	0.000433	0.00102	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—OPRM1—nicotine dependence	0.000432	0.00101	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—WASF2—nicotine dependence	0.000422	0.00099	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—WASF2—nicotine dependence	0.000415	0.000974	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—WASF1—nicotine dependence	0.000404	0.000949	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—DRD2—nicotine dependence	0.000398	0.000935	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—WASF1—nicotine dependence	0.000398	0.000934	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—OPRM1—nicotine dependence	0.00039	0.000915	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—OPRM1—nicotine dependence	0.000364	0.000854	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—DRD2—nicotine dependence	0.000362	0.000849	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—OPRM1—nicotine dependence	0.000358	0.000841	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000352	0.000827	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—WASF2—nicotine dependence	0.000342	0.000804	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—WASF1—nicotine dependence	0.000328	0.000771	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—DRD2—nicotine dependence	0.000312	0.000732	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP2A7—nicotine dependence	0.000298	0.0007	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—OPRM1—nicotine dependence	0.000296	0.000694	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—DRD2—nicotine dependence	0.000282	0.000661	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—DRD2—nicotine dependence	0.000263	0.000618	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—DRD2—nicotine dependence	0.000259	0.000608	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—DRD2—nicotine dependence	0.000214	0.000502	CbGpPWpGaD
